Total
0
Shares
Creso Pharma (ASX:CPH)  to benefit from new CBD E.U. ruling
Source: Creso Pharma
  • Creso Pharma (CPH) will benefit from a new ruling on cannabidiol (CBD) products in Europe
  • The Court of Justice of the European Union (CJEU) has ruled that CBD is not a narcotic and therefore can be freely sold in the European Union
  • This new ruling opens doors for Creso, which it will look to capitalise on immediately
  • The CBD market in Europe is expected to grow to at least €1.5 billion (around A$2.4 billion) by 2023
  • On the market today, Creso is up 17.1 per cent and is trading at 4.1 cents per share

Creso Pharma (CPH) shares are rising after a new ruling on cannabidiol (CBD) products, unlocking major potential for the company in Europe.

The Court of Justice of the European Union (CJEU) has ruled that CBD is not a narcotic as it does not appear to have any psychotropic effect or any harmful effect on human health. As a result, CBD can now freely be sold in the European Union.

The ruling was put into place after a situation where parties produced hemp CBD products in the Czech Republic, which were then imported into France for use in other products. Criminal proceedings then began because the French legislation only allows for fibre and hemp seeds to be put to commercial use.

However, it was determined that the legislation did not apply to CBD obtained from a whole hemp plant as it was not listed as an agricultural product and therefore hemp CBD products are not restricted by the relevant legislation.

"In arriving at the decision, the CJEU noted that, according to the current state of scientific knowledge, the CBD involved doesn’t appear to have any psychotropic effect or any harmful effect on human health and therefore cannot be classified as a narcotic drug," the company explained.

This new ruling opens doors for Creso, which will look to capitalise on the milestone immediately.

According to Orian Research Group, the CBD market in Europe is about €450 million (around A$728 million), representing 31 per cent of the global CBD oil market share. The market is expected to be worth at least €1.5 billion (around A$2.4 billion) by 2023.

"The decision by the CJEU unlocks a number of significant opportunities for Creso Pharma, in a market that the Company already has an established
presence," Non-Executive Chairman Adam Blumenthal said.

"The European market has always played an important role in the Company’s growth trajectory and the most recent regulatory shift will allow us to continue to progress a number of near term initiatives, engineered to unlock value for shareholders," he added.

On the market today, Creso is up 17.1 per cent and is trading at 4.1 cents per share at 1:01 pm AEDT.


Subscribe


CPH by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Founder & CEO, John Kelly - The Market Herald

" Atomo Diagnostics (ASX:AT1) ends Q2 FY21 with $24.7M in cash

Atomo Diagnostics (AT1) has released its quarterly report for the December 2020 quarter which it closed off with a healthy cash balance of
4DMedical (ASX:4DX) - CEO, Andreas Fouras - The Market Herald

" 4DMedical (ASX:4DX) to trial software in California

Medical tech company 4DMedical (4DX) has secured the first U.S. clinical pilot of its XV Lung Ventilation Analysis Software (XV LVAS).
Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial

" Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial

Little Green Pharma (LGP) has been selected as a primary supplier of medicinal cannabis oils for a national trial in France.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) advances phase two efti study for COVID-19 patients

Immutep (IMM) has announced its phase two Eftilagimod Alpha Treatment COVID (EAT COVID) study will advance with enrolment towards the randomised portion.